
SNNAQ
Healthcare · Biotechnology · $3,090 market cap
$0.00010.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2019
EPS trend, 90 days to now · 30-day revisions 1 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 31, 2022 | Time not confirmed | — | 0.00 | — |
| May 12, 2022 | Time not confirmed | — | 0.00 | — |
| Mar 17, 2022 | Time not confirmed | — | 0.00 | — |
| Nov 11, 2021 | Time not confirmed | — | 0.00 | — |
| Sep 9, 2021 | Time not confirmed | — | 0.00 | — |
| May 17, 2021 | Time not confirmed | — | 0.00 | — |
| Mar 18, 2021 | Time not confirmed | — | 0.00 | — |
| Oct 9, 2020 | Time not confirmed | — | 0.00 | — |
| May 18, 2020 | Time not confirmed | — | 0.00 | — |
| Mar 12, 2020 | Time not confirmed | -0.22 | 0.00 | +100.0% |
| Nov 12, 2019 | After the close | -0.24 | -0.13 | +45.8% |
| Aug 8, 2019 | After the close | -0.40 | -0.27 | +32.5% |
| May 8, 2019 | After the close | -0.50 | -0.63 | -26.0% |
Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the…
| Mar 14, 2019 |
| Before the open |
| -0.86 |
| -0.93 |
| -8.1% |
| Nov 8, 2018 | Before the open | -0.93 | -0.82 | +11.8% |
| Aug 9, 2018 | Before the open | -0.79 | -1.00 | -26.6% |
| May 14, 2018 | Before the open | -0.71 | -0.85 | -19.7% |
| Mar 15, 2018 | Before the open | -0.79 | -0.56 | +29.1% |